and that is where the latest Capraise will be critically important.
It will provide the funding to fast track these Studies so that we can gain the data to know if we should say YES to $130... or tell them to come back with something above $400.
Because as a shareholder, I would be more than upset if RAC sold for $26B, only to then have Zantrene get $50b+ worth of sales in the first or 2nd year of being on the market!!
So like I said, break down the Pillars, Regional Licensing, Global Oncology Spending... and I stand by the $400-$450 range I am aiming for.
Not Financial Advice, just my own dreaming.
Ann: AGM Presentations, page-65
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.030(2.01%) |
Mkt cap ! $254.2M | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.53 | $1.48 | $141.7K | 94.55K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 427 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 2999 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.51 |
Change
0.030 ( 0.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.52 | $1.53 | $1.48 | 13236 | ||
| Last updated 15.53pm 21/05/2024 ? | |||||
| RAC (ASX) Chart |